title: Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia.
abstract: The inhibition of cholesteryl ester transfer protein (CETP) has recently been shown to effectively increase high-density lipoprotein (HDL) cholesterol. This study examined the use of the CETP inhibitor JTT-705 combined with pravastatin. In a randomized, double-blind, placebo-controlled trial, 155 patients with type II dyslipidemia using pravastatin 40 mg were treated with placebo or JTT-705 300 or 600 mg. Four weeks of treatment with JTT-705 600 mg led to a 30% decrease in CETP activity (p <0.001), a 28% increase in HDL cholesterol (p <0.001), and a 5% decrease in low-density lipoprotein cholesterol (p <0.03). Combination therapy using JTT-705 and pravastatin effectively increases HDL cholesterol levels and is safe and well tolerated up to 4 weeks of administration.
authors.affiliation: Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
authors.forename: Jan Albert
authors.initials: JA
authors.lastname: Kuivenhoven
authors.forename: Greetje J
authors.initials: GJ
authors.lastname: de Grooth
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kawamura
authors.forename: Anke H
authors.initials: AH
authors.lastname: Klerkx
authors.forename: Francois
authors.initials: F
authors.lastname: Wilhelm
authors.forename: Mieke D
authors.initials: MD
authors.lastname: Trip
authors.forename: John J P
authors.initials: JJ
authors.lastname: Kastelein
mesh_terms: D000577:Amides; D002352:Carrier Proteins / Q000037:antagonists & inhibitors*; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL / Q000187:drug effects; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004952:Esters; D005260:Female; D006023:Glycoproteins / Q000037:antagonists & inhibitors*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D017035:Pravastatin / Q000627:therapeutic use*; D013438:Sulfhydryl Compounds / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000577:Amides; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D004952:Esters; D006023:Glycoproteins; D000960:Hypolipidemic Agents; D010919:Placebos; D013438:Sulfhydryl Compounds; C411602:dalcetrapib; D017035:Pravastatin